NCT00638118View on ClinicalTrials.gov

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

May 31, 2003

Conditions
Allergic Rhinitis
Interventions
DRUG

Fexofenadine

Trial Locations (1)

08807

Sanofi-Aventis, Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00638118 - Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen | Biotech Hunter | Biotech Hunter